A novel long-acting VIP analog in the guinea pig trachea in vitro

Peptides

Volumn 19, Issue 3, 1998, Pages 593-597

  Yoshihara, Shigemi ^a   Lindén, Anders ^b   Kashimoto, Kazuhisa ^c   Watanabe, Shigeaki ^a,c  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Itoham Foods Inc   (Japan)

Author keywords

Bronchodilator; Guinea pig airways; Neuropeptides; Peptidase; Smooth muscle relaxation; VIP; VIP analog

Indexed keywords

BRONCHODILATING AGENT; CAPTOPRIL; CARBACHOL; PEPTIDASE; PHOSPHORAMIDON; SALBUTAMOL; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE[15,20,21 ARGININE 17 LEUCINE];

ANIMAL TISSUE; ARTICLE; BRONCHODILATING ACTIVITY; GUINEA PIG; MALE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; TRACHEA;

ALBUTEROL; AMINO ACID SEQUENCE; ANIMALS; CAPTOPRIL; CARBACHOL; GUINEA PIGS; MALE; MOLECULAR SEQUENCE DATA; MUSCLE RELAXATION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRACHEA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 17444439445     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00457-9     Document Type: Article

References (21)

1. Barnes P. J., Dixon C. M. The effect of inhaled vasoactive intestinal polypeptide on bronchial reactivity to histamine in humans. Am. Rev. Respir. Dis. 130:1984;162-166.
2. Bellinger D. K., Lorton D., Brouxhon S., Felten S., Felten D. L. The significance of vasoactive intestinal polypeptide (VIP) immunomodulation. Adv. Neuroimmunol. 6:1996;5-27.
3. Bondesson L., Norolind K., Lidén S., Gafvelin G., Theodorsson E., Mutt V. Dual effects of vasoactive intestinal peptide (VIP) on leukocyte migration. Acta Phys. Scand. 141:1991;477-481.
4. Bolin D. R., Michalewsky J., Wasserman M. A., O'Donnel M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers. 37:1995;57-66.
5. Caughey G. H., Leidig F., Viro N. F., Nadel J. A. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J. Pharm. Exp. Ther. 24:1988;133-137.
6. Conroy D. M., St-Pierre S., Sirois P. Relaxant effects of pituitary adenylate cyclase activating polypeptide (PACAP) on epithelium-intact and -denuded guinea pig trachea a comparison with vasoactive intestinal peptide (VIP) . Neuropeptides. 29:1995;121-127.
7. Foda H. D., Sharaf H. H., Absood A., Said S. I. Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, has prolonged airway smooth muscle relaxant activity. Peptides. 16:1995;1057-1061.
8. Franconi G. M., Graf P., Lazarus S. C., Nadel J. A., Caughey G. H. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J. Pharm. Exp. Ther. 248:1989;947-951.
9. +ATPase in airway smooth muscle relaxation by vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide. Res. Com. Chem. Pathol. Pharmacol. 79:1993;11-22.
10. Kashimoto K., Nagano Y., Suitani Y., Hamanaka K., Mizumoto T., Tomizaki K., Takahata H., Nagamoto A., Ohata A., Yoshihara S., Ichimura T. Structure-activity relationship studies of PACAP 27 and VIP analog. 2nd International symposium on VIP, PACAP, and related peptides. Ann. NY Acad. Sci. 805:1996;505-510.
11. Lilly C. M., Kobzik L., Hall A. E., Drazen J. M. Effects of chronic airway inflammation on the activity and enzymatic inactivation of neuropeptides in guinea pig lungs. J. Clin. Invest. 93:1994;2667-2674.
12. Lindén, A.; Bergendal, A.; Ullman, A.; Skoogh, B. E.; Löfdahl, C. G. Formoterol and salmenterol compared with salbutamol in the isolated guinea pig trachea - difference in maximum relaxant effect and potency but not in functional antagonism. Thorax. 48:547-533; 1993.
13. Lindén A., Yoshihara S., Chan B., Nadel J. A. Inhibition of bronchoconstriction by pituitary adenylate-cyclase activating peptide (PACAP 1-27) in guinea-pigs in vivo. Br. J. Pharmacol. 115:1995;913-916.
14. Lindén A., Cardell L. O., Yoshihara S., Stjärne P., Nadel J. A. PACAP 1-38 as an inhaled bronchodilator in guinea pigs in vivo. Peptides. 19:1998;93-98.
15. Liu L. W., Sata T., Kubota E., Paul S., Said S. Airway relaxant effect of vasoactive intestinal peptide (VIP) selective potentiation by phosphoramidon, an enkephalinase inhibitor . Am. Rev. Respir. Dis. 135:1987;A86.
16. Morice A., Unwin R. J., Sever P. S. Vasoactive intestinal peptide causes bronchodilation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet. 2:1983;1225-1226.
17. Palmer J. B. D., Cuss F. M. C., Barnes P. J. VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. J. Appl. Physiol. 61:1986;1322-1328.
18. Sakai N., Tamaoki J., Kanemura T., Isono K., Takeyama K., Takeuchi S., Takizawa T. Vasoactive intestinal peptide stimulates ciliary motility in rabbit tracheal epithelium modulation by neutral endopeptidase . Reg. Peptides. 34:1991;33-41.
19. Tang H., Welton A., Ganea D. Neuropeptide regulation of cytokine expression effects of VIP and Ro 25-1553 . J. Interferon Cytokine Res. 15:1995;993-1003.
20. Tam E. K., Caughey G. H. Degradation of airway neuropeptides by human lung tryptase. Am. J. Cell. Mol. Biol. 3:1990;27-32.
21. Tam E. K., Franconi G. M., Nadel J. A., Caughey G. H. Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am. J. Resp. Cell. Mol. Biol. 2:1990;449-452.